Clinical trials: Polycythemia Vera, open to volunteers
Polycythemia Vera
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any…
- Trial name
- MITHRIDATE (NCT04116502)
- Testing
- Ruxolitinib, Hydroxycarbamide, Interferon-Alpha
- Where
- 55 sites in United Kingdom
- Volunteers
- 586 people
- Sponsor
- University of Birmingham
Polycythemia Vera, ET (Essential Thrombocythemia)
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV)…
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET)
- Trial name
- NCT07362225
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- MPN Research Foundation
Primary Myelofibrosis, Secondary Myelofibrosis
Research Platform Myelofibrosis and Anemia
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of…
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- RHODOLITE (NCT06976918)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- iOMEDICO AG
Healthy Volunteers
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in…
- Trial name
- NCT07527221
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eilean Therapeutics AU Pty Ltd
Polycythemia Vera (PV)
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon.
- Trial name
- NCT07232290
- Testing
- Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Myeloproliferative Neoplasm
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
First-line treatment for patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis is based on hydroxyurea or pegylated interferon.
- Trial name
- BioPredictor (NCT05440838)
- Testing
- Next-generation sequencing
- Where
- 6 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Angers
Polycythemia Vera (PV), Myelofibrosis (MF)
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
This study will test an experimental drug called ZE74-0282 in people with certain blood disorders caused by a specific mutation called JAK2 V617F.
- Trial name
- NCT07529951
- Testing
- ZE74-0282
- Volunteers
- 60 people
- Sponsor
- Eilean Therapeutics
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
- Trial name
- NCT06327100
- Testing
- Ruxolitinib, Tasquinimod
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Polycythemia Vera, Essential Thrombocythaemia
Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History
Philadelphia-negative myeloproliferative neoplasms (MPNs) occur sporadically and are due to somatic mutations in the JAK2 (Janus kinase 2), CALR (calreticulin) and MPL (thrombopoietin receptor) genes.
- Conditions
- Polycythemia Vera, Essential Thrombocythaemia, Myelofibrosis
- Trial name
- NCT06923670
- Testing
- NGS testing, NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
- Volunteers
- 496 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential…
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT06073847
- Testing
- Fedratinib
- Where
- 3 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Bristol-Myers Squibb
Polycythemia Vera
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
This is a multicenter, open-label Phase I clinical trial of BEBT-507 in subjects with polycythemia vera(PV). Phase Ia is a single-agent dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK)…
- Trial name
- NCT07012109
- Testing
- BEBT-507 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- BeBetter Med Inc
Polycythemia Vera
A Study of Rusfertide in Adults With Polycythemia Vera in China
Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made.
- Trial name
- NCT07765602
- Testing
- Rusfertide
- Volunteers
- 24 people
- Sponsor
- Takeda
Polycythemia Vera, Essential Thrombocythemia
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F
- Trial name
- AVAJAK (NCT05198960)
- Testing
- Direct Oral Anticoagulants, Low-dose aspirin
- Where
- 42 sites in France
- Volunteers
- 1,308 people
- Sponsor
- University Hospital, Brest
Myelofibrosis; Anemia, Anemia
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with…
- Conditions
- Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
- Trial name
- NCT05320198
- Testing
- DISC-0974
- Where
- 35 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Disc Medicine, Inc
Polycythemia Vera
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.
- Trial name
- PV (NCT05870475)
- Testing
- Ruxolitinib, Pegylated interferon α-2b
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF)
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera…
- Conditions
- Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
- Trial name
- NCT05835466
- Testing
- reparixin
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Polycythemia Vera
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Polycythemia vera (PV) is a rare blood cancer in which the body makes too many red blood cells. This can make the blood thicker and may increase the risk of serious health problems such as blood clots.
- Trial name
- NCT07648030
- Testing
- Rusfertide
- Where
- 9 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Takeda
Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Revumenib in Patients With Myelofibrosis
This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis.
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- MPN-RC 129 (NCT07734077)
- Testing
- Revumenib, Ruxolitinib, FEDRATINIB
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- John Mascarenhas
Polycythemia
Effect of Phlebotomy on Heartrate in Polycythemia Patients
Single-centre, observational within-subject design: patients that undergo phlebotomies regularly for polycythemia will be measured continuously by wearables one week before until one week after a phlebotomy, for three…
- Trial name
- NOSFERATU (NCT05396170)
- Testing
- phlebotomy
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Myelofibrosis, Primary Myelofibrosis
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
- Trial name
- NCT06516406
- Where
- 26 sites in Italy
- Volunteers
- 1,055 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna